Get the Stockscreener App
17.97
3.04%
0.53
Pre-market:
18.99
1.02
+5.68%
Seaport Therapeutics Inc stock is traded at $17.97, with a volume of 199.07K.
It is up +3.04% in the last 24 hours and up +6.93% over the past month.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
See More
Previous Close:
$17.44
Open:
$17.41
24h Volume:
199.07K
Relative Volume:
1.57
Market Cap:
$961.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-24.97
EPS:
-0.7198
Net Cash Flow:
-
1W Performance:
+1.76%
1M Performance:
+6.93%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.31
$18.19
1-Week Range:
$16.15
$18.78
52-Week Range:
$14.85
$19.30
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Name
Seaport Therapeutics Inc
Sector
Industry
Phone
617-807-4062
Address
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
17.97 | 933.57M | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Stock (SPTX) Latest News
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - London South East
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
Seaport Therapeutics reports phase 1 data for anxiety drug By Investing.com - Investing.com South Africa
Seaport Therapeutics 1Q 2026: Net loss $(25.4M), EPS $(10.34) — 10-Q Summary - TradingView
Seaport Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
SPTX: Q1 2026 net loss rose to $25.4M; cash and investments total $212.6M post-IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, vs. FactSet Est of $10.64 Loss - marketscreener.com
Seaport Therapeutics reports phase 1 data for anxiety drug - Investing.com
SPTX: Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment - TradingView
Seaport Therapeutics reports Q1 2026 net loss of $25.4M, cash $212.6M before $260M IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, Vs. FactSet Est of $10.64 Loss - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers - TradingView
Press Release: Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - The Joplin Globe
Seaport Therapeutics announces positive Phase 1 MAD results for GlyphAgo - grafa.com
SPTX Stock Price and Chart — NASDAQ:SPTX - TradingView
Seaport Therapeutics (SPTX) Stock Trends and Sentiment 2026 - MarketBeat
Citi Sticks to Its Buy Rating for Seaport Therapeutics, Inc. (SPTX) - The Globe and Mail
Seaport Therapeutics (SPTX) Stock Forecast and Price Target 2026 - MarketBeat
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences - Business Wire
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
J.P. Morgan Initiates Seaport Therapeutics(SPTX.US) With Buy Rating, Announces Target Price $42 - Moomoo
Leerink Partners Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Latest SPTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Seaport Therapeutics Inc Stock (SPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):